Search research articles
Contact Us
Filters
Showing results (1-10 of 41) with videos related to
Page
of 5
Sort By:
Mycoses
|
June 14, 2019
Mucormycosis in South America: A review of 143 reported cases
Marcio Nucci, Marc Engelhardt, Kamal Hamed
Journal of Physics. Condensed Matter : an Institute of Physics Journal
|
September 2, 2025
Kinetic contributions rule diffusion of mass in the liquid ternary eutectic E1 Ag-Al-Cu alloy
Marc Engelhardt, Florian Kargl, Elke Sondermann, et al.
The New England Journal of Medicine
|
December 29, 2023
Ceftobiprole for Staphylococcus aureus Bacteremia. Reply
Thomas L Holland, Marc Engelhardt, Vance G Fowler
Trials
|
April 15, 2008
A randomized double-blind placebo-controlled trial to investigate the effects of nasal calcitonin on bone microarchitecture measured by high-resolution peripheral quantitative computerized tomography in postmenopausal women - study protocol
Laura Richert, Brigitte Uebelhart, Marc Engelhardt, et al.
Future Microbiology
|
June 22, 2021
A <i>post hoc</i> analysis of two Phase III trials showing the efficacy and tolerability of ceftobiprole in East Asian patients
Haihui Huang, Lei Gao, Marc Engelhardt, et al.
The Journal of Antimicrobial Chemotherapy
|
November 27, 2018
Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases
Thomas Kaindl, David Andes, Marc Engelhardt, et al.
Future Microbiology
|
May 7, 2021
Efficacy and safety of ceftobiprole in patients aged 65 years or older: a <i>post hoc</i> analysis of three Phase III studies
Tobias Welte, Thomas Wl Scheeren, J Scott Overcash, et al.
Scientific Reports
|
May 15, 2023
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies
Kamal Hamed, Marc Engelhardt, Laura L Kovanda, et al.
BMC Infectious Diseases
|
February 28, 2019
Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials
Thomas W L Scheeren, Tobias Welte, Mikael Saulay, et al.
Expert Review of Anti-Infective Therapy
|
July 11, 2025
A plain language summary of the safety and effectiveness of isavuconazole for the treatment of serious fungal disease in children with a weakened immune system
Antonio C Arrieta, Laura Kovanda, Marc Engelhardt, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 41) with videos related to
Sort By:
Page
of 5
Mycoses
|
June 14, 2019
Mucormycosis in South America: A review of 143 reported cases
Marcio Nucci, Marc Engelhardt, Kamal Hamed
Journal of Physics. Condensed Matter : an Institute of Physics Journal
|
September 2, 2025
Kinetic contributions rule diffusion of mass in the liquid ternary eutectic E1 Ag-Al-Cu alloy
Marc Engelhardt, Florian Kargl, Elke Sondermann, et al.
The New England Journal of Medicine
|
December 29, 2023
Ceftobiprole for Staphylococcus aureus Bacteremia. Reply
Thomas L Holland, Marc Engelhardt, Vance G Fowler
Trials
|
April 15, 2008
A randomized double-blind placebo-controlled trial to investigate the effects of nasal calcitonin on bone microarchitecture measured by high-resolution peripheral quantitative computerized tomography in postmenopausal women - study protocol
Laura Richert, Brigitte Uebelhart, Marc Engelhardt, et al.
Future Microbiology
|
June 22, 2021
A <i>post hoc</i> analysis of two Phase III trials showing the efficacy and tolerability of ceftobiprole in East Asian patients
Haihui Huang, Lei Gao, Marc Engelhardt, et al.
The Journal of Antimicrobial Chemotherapy
|
November 27, 2018
Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases
Thomas Kaindl, David Andes, Marc Engelhardt, et al.
Future Microbiology
|
May 7, 2021
Efficacy and safety of ceftobiprole in patients aged 65 years or older: a <i>post hoc</i> analysis of three Phase III studies
Tobias Welte, Thomas Wl Scheeren, J Scott Overcash, et al.
Scientific Reports
|
May 15, 2023
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies
Kamal Hamed, Marc Engelhardt, Laura L Kovanda, et al.
BMC Infectious Diseases
|
February 28, 2019
Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials
Thomas W L Scheeren, Tobias Welte, Mikael Saulay, et al.
Expert Review of Anti-Infective Therapy
|
July 11, 2025
A plain language summary of the safety and effectiveness of isavuconazole for the treatment of serious fungal disease in children with a weakened immune system
Antonio C Arrieta, Laura Kovanda, Marc Engelhardt, et al.
Page
of 5